Advances in RAS Inhibition in Pancreatic Ductal Adenocarcinoma - Episode 2

The Prevalence of RAS Mutations in Metastatic PDAC

,

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the prevalence of RAS mutations in pancreatic ductal adenocarcinoma.

EP. 1: Explaining the Continued Interest in RAS Inhibition for PDAC
Now Viewing
EP. 2: The Prevalence of RAS Mutations in Metastatic PDAC
EP. 3: The Current and Evolving Role of KRAS G12C and Pan-KRAS Inhibitors in Metastatic PDAC
EP. 4: How the Mechanisms of KRAS(ON) Inhibitors Differ From KRAS(OFF) Inhibitors

Related Content:

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAdvances in RAS Inhibition in Pancreatic Ductal AdenocarcinomaOncLive News Network®Gastrointestinal Cancer
PLN-101095 Plus Pembrolizumab Displays Activity in ICI-Refractory Advanced Solid Tumors
PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD
Revisit Every OncLive On Air Episode From November 2025